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osting by EAbstract The objective of this study was to evaluate Kollidon SR for the development of extended
release Albuterol Sulphate matrix tablets in comparison with other polymers as Hydroxypropylm-
ethylcellulose K15M, Carbopol 71G NF, and Eudragit L100-55. The mechanical properties of the
tablets were improved as concentration of Kollidon SR or other polymers increased. It was found
that Kollidon SR 30% (w/w) and HPMC 30% (w/w) tablets have f2 similarity factor of 83.5 in their
Albuterol Sulphate dissolution proﬁle. The marketed product was found to release 99.7% of drug
content within 8 h, while Kollidon SR and HPMC tablets with 30% (w/w) polymer concentration
level released 92.7% and 92.9% respectively of drug content within 8 h. Kollidon SR has a unique
character of maintaining tablets geometric shape until the end of dissolution test, this is mainly due
to the water insoluble content, polyvinyl acetate, forming 80% (w/w) of Kollidon SR, while the
remaining content 20% (w/w) is the water soluble, polyvinylpyrrolidone, responsible for pore for-
mation causing a diffusion controlled release. Drug release from all previous formulations is best
described to be controlled by more than one kinetic mechanism of release.
In conclusion, Kollidon SR and HPMC and Carbopol were found to be potential candidates for
the development of extended release of Albuterol Sulphate tablets.
ª 2010 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.(W. Sakr).
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lsevier1. Introduction
Bronchial asthma, a common chronic disorder of the airways
that is complex and characterized by variable and recurring
symptoms, airﬂow obstruction, bronchial hyper-responsive-
ness (bronchospasm), and an underlying inﬂammation (Renz,
2001). Albuterol Sulphate, the most widely prescribed bron-
chodilator in the United Kingdom on the control of asthma
(Dennis et al., 2000) that is a fairly water soluble drug, well ab-
sorbed orally and throughout the gastrointestinal tract, and
the peak plasma levels are attained within 1–3 h. It is
extensively metabolized after oral administration mainly via
20 W. Sakr et al.conjugation mechanism and has biological half-life of about
4–6 h (Sweetman and Martindale, 2005). As a result of the
quick absorption and short half-life, it is administered orally
3–4 times a day. Due to these properties, it will be more effec-
tive to deliver this drug at a controlled but reduced input rate
rather than as an oral bolus dose from a conventional immedi-
ate release dosage form.
Many different systems are used to improve the clinical
efﬁcacy of drugs having short half-lives as well as to increase
patient compliance by controlling the rate of drug delivery
(Claxton et al., 2001), including enteric coating, osmotic
pumps, prodrugs, transdermal patches and matrix tablets.
These formulations are designed to deliver drugs at a prede-
termined rate over a wide range of conditions and durations of
therapeutic treatments (Reddy et al., 2003). One of the most
commonly used methods of developing controlled release for-
mulations for therapeutic agents is to include them in matrix
tablets prepared by direct compression as they are easy to
manufacture and their preparation involves few processing
variables (Corti et al., 2008). Using a suitable rate controlling
polymer, the matrix can be tableted by direct compression or
conventional wet granulation method. Swellable matrix sys-
tems with anomalous release kinetics are suitable solutions
for drug release control intended for oral administration (Co-
lombo et al., 2000). The resulting release mechanism depends
on the relative importance of tablet relaxation and drug diffu-
sion rate and by adjusting these two rates; it is possible simul-
taneously to control the release mechanism and the release rate
(Colombo et al., 1990). Different methods are used to con-
struct sustained release matrix system either by trial and error
method or by using appropriate statistical design and optimi-
zation technique to obtain tablets with predictable drug release
properties (Sa´nchez-Lafuente et al., 2002; Mandal et al., 2007).
From an economical point of view the production of sustained
release tablets by direct compression is of a great promise. In
this respect Kollidon SR, a convincing excipient is expected
to be easily applicable for a broad selection of different drugs
(Siepmann et al., 2010). It is a free-ﬂowing non hygroscopic
powder consisting of polyvinyl acetate (80%, w/w) and polyvi-
nylpyrrolidone (20%, w/w) combined as a physical mixture
(Kolter et al., 2001). Kollidon SR has a unique character of
maintaining tablets geometric shape until the end of dissolu-
tion test, this is mainly due to its major component; the water
insoluble polyvinyl acetate, while the minor water soluble part;
polyvinylpyrrolidone, is responsible for pore formation caus-
ing diffusion controlled release mechanism (Draganoiu et al.,
2001). Another polymer of great promise in matrix tablets for-
mulations is Carbopol that is an oral Pharmaceutical grade of
the carbomers. It is a synthetic, high molecular weight cross-
linked polymer of acrylic acid, readily hydrates, absorbs water
and swells (Khan and Jiabi, 1998). In addition, its hydrophilic
nature and highly crosslinked structure make it a potential
candidate for use in controlled drug delivery systems (Parojcic
et al., 2004).
2. Materials and methods
2.1. Materials
The following materials were used as received: Albuterol
Sulphate, a gift from Riyadh Pharma (Riyadh, KSA). Polyvi-nyl-acetate and povidone based polymer (Kollidon SR) BASF
(Ludwigshafen, Germany), Hydroxypropylmethylcellulose
K15M (Hypermellose K15M), dibasic calcium phosphate
dehydrate (Emcompress) and siliciﬁed microcrystalline cellu-
lose (Prosolv) were donated from JRS Pharma (Germany).
Carbopol 71G NF was a gift from Lubrizol (USA), Eudragit
L100-55 was a donation from Colorcon Ltd. (England)
and magnesium stearate purchased from Riedel-de Hae¨n
(Germany). All other chemicals used were of high analytical
grade.
2.2. Methods
2.2.1. Preparation of tablets
All tablet formulations with different drug to polymer ratios
were prepared by direct compression technique (Formulations
I–XIII, Table 1). All powders were passed through 315 l sieve
ASTM (American Society of Testing and Materials). Albuterol
Sulphate was ﬁrst mixed with Prosolv in a geometric dilution
using Turbula mixer (ERWEKA, GERMANY) for 5 min then
mixed with the remaining ingredients except magnesium stea-
rate for 10 min. Magnesium stearate was then added and
mixed for 1 min. Korsch single punch tablet machine (Berlin,
Germany) was used to press tablets of about 300 mg average
weight and 4.4 mm average thickness using concave punches
of 8 mm diameter.
2.2.2. Evaluation of tablets
2.2.2.1. Thickness. The thickness of the tablets was determined
using a thickness gauge (Starrett, ATHOL, MA, USA). Ten
tablets from each batch were used and the average values were
calculated.
2.2.2.2. Weight variation. To study weight variation, 20 tablets
of each formulation were weighed individually using four dec-
imals digital electronic balance (METTLER-TOLEDO AJ150,
Switzerland).
2.2.2.3. Drug content. Ten tablets were weighed individually,
and the drug was extracted in 50 ml distilled water with soni-
cation for 2 min. The actual drug content was determined
using a photo-diode array UV–visible spectrophotometer
(BELING RAYLEIGH, Japan) at 275 nm and the drug con-
centration was determined using the constructed standard cal-
ibration curve, covering the whole absorption range from
0.082 ± 0.004 to 0.857 ± 0.050 for drug solution concentra-
tion from 3.0 to 30.0 lg/ml respectively made in triplicate
and R2 = 0.9998 ± 0.02. The straight line equation was:
(y= 0.004 + 0.027x).
2.2.2.4. Hardness and friability. For each formulation batch,
the hardness and friability of 10 and 20 tablets, respectively,
were determined using hardness tester (ERWEKA TBH-28,
Germany) and the friabilator (ELECTROLAB, India), respec-
tively. The tablet compression machine was suitably adjusted
to produce tablets of uniform weight and thickness. Tablets
hardness was checked at the start and during the compression
process to control an acceptable range of tablet hardness.
2.2.2.5. In vitro release studies (dissolution). The in vitro
dissolution studies were carried out using USP dissolution
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Effect of Kollidon SR on the release of Albuterol Sulphate from matrix tablets 21apparatus type II (LOGAN UDT-804) with paddle rotating at
50 rpm. The dissolution medium consisted of distilled water
(250 ml), maintained at 37 ± 0.5 C. The drug release at differ-
ent time intervals was measured at 225 nm (Tanwar, 2005) and
the corresponding cumulative percent of drug released was
determined using the constructed standard calibration curve
at this wave length covering the range for assay. A model inde-
pendent approach was recommended in FDA guidance using
similarity factor (f2) as one of the mathematical models of dis-
solution to compare between the release data of two dissolu-
tion proﬁles, one is the test and the other is the reference at
different time intervals (FDA, 2000), as the following
equation:
f2 ¼ 50  log 1þ ð1=nÞ
Xn
t¼1
ðRt  TtÞ2
" #0:5
 100
8<
:
9=
;
where n is the number of data points, Rt is the amount released
from the reference at time t, and Tt is the amount released
from the test at time t. The two products are similar if f2 value
equals 50–100.
2.2.2.6. In vitro drug release (kinetics and mechanism). To
know the mechanism of drug release from these formulations,
the data were ﬁtted to zero order (cumulative amount of drug
released vs time), ﬁrst-order (log cumulative percentage of
drug remaining vs time), Higuchi’s (cumulative percentage of
drug released vs square root of time), and Korsmeyer’s (log
cumulative percentage of drug released vs log time) equations
(Kumar et al., 2010).
 Zero order equation,
ft ¼ K0t
where ft is the fraction dissolved at time t and K0 is the
apparent dissolution rate constant or zero order rate
constant.
 First-order equation,
logQt ¼ logQ0  K1t=2:303
where Qt is the amount released at time t, Q0 is the initial
amount of drug in solution and K1 is the ﬁrst order rate
constant.
 Higuchi’s equation,
Ft ¼ KH  t1=2
where Ft is the fraction dissolved at time t and KH is the
Higuchi dissolution constant.
 Korsmeyer et al.’s equation (Power law),
Mt=M1 ¼ atn
where Mt is the amount of drug released at time t, M1 is
the amount of drug released after inﬁnite time (total drug
in a dosage form), a is the Korsmeyer’s dissolution rate
constant and n is the release exponent.
2.2.2.7. Tablets swelling and erosion investigation. This test was
used as a qualitative guidance to monitor the development of
physical changes in the tablets morphology when placed in
the dissolution medium with some modiﬁcation for the test
presented by Sriamornsak et al. (2007a,b). Tablets are placed
22 W. Sakr et al.in the dissolution apparatus under the same conditions men-
tioned under the dissolution tests. Using a digital camera (Ni-
kon CoolPix L5 digital camera, Japan, 3.6· Zoom-NIKKOR
lens and 2.5-in. LCD display) tablets are photographed at zero
time, 1.0, 6.0 and 12.0 h.
2.2.3. Statistical analysis of data
Graphpad Instat Version 3.05 and Graphpad Prism Version
5.01 programs were the software for statistical analysis of
our data. Dissolution proﬁles can be investigated for differ-
ences in both level and shape using a parametric statistical test
of signiﬁcance; ANALYSIS OF VARIANCE (ANOVA) or
using Kruskal–Wallis Test (Nonparametric ANOVA, cor-
rected for ties) followed by Dunn’s Multiple Comparisons Test
depending on both size and normality of our collected data
that provide detailed information about dissolution data which
can be useful also in formulation development to compare be-
tween the releases of more than two groups (Qazi et al., 2003)
and inform us about the signiﬁcance of difference between
more than two means of data also if the probability of differ-
ence is due to chance or not at a deﬁnite degree of freedom
(Yuksel et al., 2000).
3. Results and discussion
The produced tablets (Formulations I–XIII, Table 1); had
thickness ranged from 4.45 ± 0.008 to 4.81 ± 0.006 mm
(Table 2). Drug content was found to be uniform among dif-
ferent batches of the tablets and ranged from 94.36
(RSD= 2.14%) to 102.59 (RSD= 3.48%). The hardness
and percentage friability of the tablets of all batches ranged
from 2.43 ± 0.09 to 7.45 ± 0.52 KP and 0.19 ± 0.11% to
1.01 ± 0.51%, respectively (Table 2). Albuterol Sulphate
tablets dissolution curves with different polymers at ratios
10–30% (w/w) showed a marked slowing in drug release as
the polymer content was increased; Carbopol 71G NF tablets
(Fig. 1A), Eudragit L100-55 tablets (Fig. 1B), HPMC K15M
tablets (Fig. 1C) and Kollidon SR tablets (Fig. 1D). It was
obvious from the swelling behavior of tablets in water during
dissolution test at different time intervals that each polymer
has a characteristic physical manner (Fig. 2). It was noted that
HPMC tablets showed some degree of swelling along the dis-
solution period (Fig. 2C), but less than Carbopol matrices thatTable 2 Physical properties of pressed tablets.
Tablets Average weight, g
(±SD)
Thickness, mm
(±SD)
Formulation I 0.3045 (0.001) 4.45 (0.008)
Formulation II 0.3014 (0.004) 4.48 (0.006)
Formulation III 0.3058 (0.002) 4.49 (0.009)
Formulation IV 0.3069 (0.001) 4.81 (0.006)
Formulation V 0.3024 (0.002) 4.48 (0.009)
Formulation VI 0.3040 (0.001) 4.49 (0.007)
Formulation VII 0.3038 (0.001) 4.46 (0.018)
Formulation VIII 0.3017 (0.001) 4.46 (0.007)
Formulation IX 0.3001 (0.001) 4.49 (0.008)
Formulation X 0.2983 (0.002) 4.49 (0.012)
Formulation XI 0.3009 (0.001) 4.49 (0.006)
Formulation XII 0.3013 (0.002) 4.46 (0.008)
Formulation XIII 0.2983 (0.002) 4.49 (0.012)showed pronounced swelling behavior in the dissolution med-
ium (Fig. 2A). Kollidon SR matrix tablets showed no signiﬁ-
cant swelling (Fig. 2D); while Eudragit matrix tablets
disintegrated into particles during dissolution phase
(Fig. 2B), which could be referred to its pH-dependant solubil-
ity within the pH range of 5.5–7.0 and since dissolution med-
ium is distilled water of nearly neutral pH, so enforced
Eudragit tablets to disintegrate rapidly as it is a pH sensitive
polymer (Zahirul et al., 1999). Increasing the amount of Car-
bopol in tablets resulted in a reduction in the drug release rate
which is in agreement with the results obtained from the work
of Khan and Jiabi (1998) and Tapia-Albarran and Villafuerte-
Robles (2004). It was noticed that Kollidon SR has a unique
character of maintaining tablets geometric shape until the
end of dissolution test (Fig. 2D), that could be isolated to
the water insoluble part; polyvinyl acetate, forming 80% (w/
w) of Kollidon SR that maintains tablet shape, while the
remaining part 20% (w/w) is the water soluble, polyvinylpyr-
rolidone that dissolves in water leaving open pores within
which water accesses to dissolve the drug causing a diffusion
controlled release mechanism (Kolter et al., 2001). The mar-
keted product also was able to maintain its geometric shape
along over dissolution and showed no sign of swelling
(Fig. 2E), which may be attributed to its different formulation
as a sustained release tablets belonging to Osmotic Pump sys-
tem that was releasing only from a small pore drilled in its
semi-permeable membrane that may be hydrophobic polymer.
Osmotic Pump system depends on utilizing the osmotic pres-
sure as an energy source (driving force), the semi-permeable
membrane controls water inﬂow, generating hydrodynamic
pressure inside the dosage form and thereby controlling drug
release (Malaterre et al., 2009). The marketed tablet osmotic
pressure inside was higher than the outer dissolution medium
permitting water to pass though the pore in the coat to dissolve
tablets contents and so controlled Albuterol Sulphate release
for a predetermined period of time.
The in vitro release results at the 30% (w/w) polymer con-
centration were compared with a marketed controlled release
product (Fig. 3). It was found that Kollidon SR 30% (w/w)
and HPMC 30% (w/w) have f2 similarity factor of 83.5 in their
Albuterol Sulphate dissolution proﬁle compared to each other,
but had f2 = 51.6 and 52.1, respectively, with the marketed
product. The marketed product was found to release 99.7%Hardness, KP
(±SD)
Friability, %
(±SD)
Drug content, %
(±RSD)
2.43 (0.09) 1.01 (0.51) 94.36 (2.14)
3.33 (0.22) 0.55 (0.02) 97.79 (3.93)
7.45 (0.52) 0.21 (0.09) 102.59 (3.48)
6.54 (0.35) 0.19 (0.11) 102.37 (5.11)
2.90 (0.14) 0.95 (0.21) 101.85 (3.29)
3.95 (0.26) 0.58 (0.12) 101.77 (3.48)
5.50 (0.25) 0.39 (0.51) 100.60 (2.27)
2.90 (0.16) 0.76 (0.07) 101.57 (3.67)
2.91 (0.17) 0.73 (0.06) 101.86 (1.93)
3.88 (0.22) 0.43 (0.32) 102.15 (1.92)
2.98 (0.17) 0.82 (0.45) 101.53 (3.25)
4.28 (0.26) 0.46 (0.33) 98.12 (3.43)
3.88 (0.22) 0.43 (0.42) 102.15 (5.75)
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Figure 1 Albuterol Sulphate tablets dissolution curves (mean + SD, n= 6), with different polymers at ratios 10–30% (w/w): (A)
Carbopol 71G NF tablets, (B) Eudragit L100-55 tablets, (C) HPMC K15M tablets and (D) Kollidon SR tablets.
Figure 2 Swelling behavior of different tablets in water at different time intervals: (A) Carbopol 30% tablets, (B) Eudragit 30% tablets,
(C) HPMC 30% tablets, (D) Kollidon 30% tablets and (E) Marketed product.
Effect of Kollidon SR on the release of Albuterol Sulphate from matrix tablets 23of drug content within 8 h while Kollidon SR and HPMC at
30% (w/w) polymer concentration level, released 92.7% and
92.9% respectively of drug content within 8 h. Eudragit tabletsdissolution proﬁle was found to be instantaneous rather than
sustained effect and close to that of the immediate release tab-
lets (control tablets) that conﬁrm the reason mentioned before
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Figure 3 Comparison of tablets dissolution at 30% polymer
concentration results indicated as; (mean + SD, n= 6).
Figure 5 Time required for 50% drug release at 30% polymer
concentration.
24 W. Sakr et al.about the pH-dependent dissolution (Zahirul et al., 1999). The
release mechanism of HPMC tablets matrix system can be de-
scribed on the basis of it high water absorption, fast hydration
and swelling to form an outer pseudo-gel layer controlling
drug release from the inner to the outer side of the tablets
(Hardy et al., 2007). Breakage of hydrogen bonds as HPMC
ﬁbers relax and uncoil leaving behind large interstitial pores
and facilitating liquid entry in addition to the inter-particular
wicking of the liquid due to the ﬁbrous nature of HPMC also
assists in the liquid entry (Vyas et al., 1989). As time proceeds,
these voids are blocked by the swollen HPMC causing them to
become inaccessible pores hindering the drug release. Liquid in
this case is taken up mainly by slow diffusion and the rate
of drug release is controlled by the gel layer thickness that[A]
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Figure 4 Albuterol Sulphate tablets hardness and friability tests res
ratios 10–30% (w/w): (A) Carbopol 71G NF tablets, (B) Eudragit L100depends on HPMC amount and its molecular weight (Vatsaraj
et al., 2002; Kumar et al., 2007). This also may be due to the
increase in viscous drag which is dependent on the molecular
weight of HPMC used as the HPMC of high molecular weight
tends to swell faster than HPMC of low molecular weight and
this may block up the open pores prematurely, impeding fur-
ther liquid entry (Wan et al., 1991).
The mechanical properties of the Albuterol Sulphate tablets
were improved (increased hardness and reduced friability) as
the polymers concentration were increased; Carbopol 71G
NF tablets at ratios 10–30% (w/w) (Fig. 4A), Eudragit
L100-55 tablets at ratios 10–30% (w/w) (Fig. 4B), HPMC
K15M tablets at ratios 10–30% (w/w) (Fig. 4C), Kollidon
SR tablets at ratios 10–30% (w/w) (Fig. 4D). Some batches
were of low or high hardness values, but this is not entirely
dependent on the compression force or the machine used but
mainly due to the nature and cohesiveness of the polymer itself
as shown in Fig. 4. Time required for 50% drug release at 30%[C]
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ults indicated as; (mean + SD, n= 6), with different polymers at
-55 tablets, (C) HPMC K15M tablets and (D) Kollidon SR tablets.
Table 3 Kinetics of drug release by mathematical processing of dissolution data.
Zero order plotsa First-order plotsb Higuchi’s plotsc Korsmeyer et al.’s plotd
Regression
coeﬃcient (R2)
Regression
coeﬃcient (R2)
Regression
coeﬃcient (R2)
Regression
coeﬃcient (R2)
Slope
(n)
Carbopol tablets (30%,
w/w)
0.9296 0.8100 0.9857 0.9946 0.8141
Eudragit tablets (30%,
w/w)
0.5712 0.7805 0.7102 0.8251 0.2226
HPMC tablets (30%,
w/w)
0.8963 0.9533 0.9692 0.9821 0.5023
Kollidon SR tablets
(30%, w/w)
0.9129 0.9498 0.9782 0.9862 0..5000
Marketed product 0.8926 0.8673 0.9613 0.9687 0.8460
a Zero order equation: ft= K0t.
b First-order equation: log Qt= log Q0  K1t/2.303.
c Higuchi’s equation: Ft = KHt
1/2.
d Korsmeyer et al.’s equation: Mt/M1= at
n.
Table 4 Kruskal–Wallis Test (Nonparametric ANOVA, cor-
rected for ties) followed by Dunn’s Multiple Comparisons Test.
Group Number of points Sum of ranks Mean of ranks
(A) Carbopol tablets (10–30%)
1.0 h 4 20.000 5.000
2.0 h 4 32.000 8.000
4.0 h 4 45.000 11.250
6.0 h 4 46.000 11.500
12.0 h 4 67.000 16.750
Kruskal–Wallis statistic KW= 8.963 (corrected for ties)
(B) Eudragit tablets (10–30%)
1.0 h 4 27.000 6.750
2.0 h 4 38.500 9.625
4.0 h 4 41.500 10.375
6.0 h 3 29.500 9.833
12.0 h 4 53.500 13.375
Kruskal–Wallis statistic KW= 2.836 (corrected for ties)
(C) HPMC tablets
1.0 h 4 18.000 4.500
2.0 h 4 27.500 6.875
4.0 h 4 42.500 10.625
6.0 h 4 57.000 14.250
12.0 h 4 65.000 16.250
Kruskal–Wallis statistic KW= 11.095 (corrected for ties)
(D) Kollidon SR tablets (10–30%)
1.0 h 4 22.000 5.500
2.0 h 4 33.000 8.250
4.0 h 4 39.000 9.750
6.0 h 4 42.000 10.500
Kruskal–Wallis statistic KW= 2.596 (corrected for ties)
Effect of Kollidon SR on the release of Albuterol Sulphate from matrix tablets 25polymer concentration (Fig. 5) showed that the Eudragit tab-
lets requires minimum time for 50% Albuterol release that is
about 0.5 h, while the Carbopol consumed much time about
5.0 h to reach 50% Albuterol release. Kollidon SR and HPMC
have similar time required to achieve about 50% Albuterol
release from tablets.
To know the mechanism of drug release from these formu-
lations, the data were treated according to zero order (cumula-
tive amount of drug released vs time), ﬁrst-order (log
cumulative percentage of drug remaining vs time), Higuchi’s
(cumulative percentage of drug released vs square root of
time), and Korsmeyer et al.’s (log cumulative percentage of
drug released vs log time) pattern for kinetics of drug release
during dissolution process (Reddy et al., 2003).
As clearly indicated in Table 3, the formulations did not
follow a zero-order release pattern. When the data were plot-
ted according to the ﬁrst-order equation, Eudragit tablets
showed a ﬁrst order release, with regression value of 0.7805.
Release of the drug from a matrix tablet containing Eudragit
polymer generally involves factors of diffusion. Diffusion is re-
lated to transport of drug from the dosage matrix into the
in vitro study ﬂuid depending on the concentration. The other
formulations showed to be best expressed by Higuchi’s equa-
tion (Higuchi, 1963), as the plots showed high linearity with
regression value of 0.9857, 0.9692, 0.9782 and 0.9613 for Car-
bopol, HPMC, Kollidon and Marketed product, respectively.
To conﬁrm the diffusion mechanism, the data were ﬁt into
Korsmeyer et al.’s equation (Korsmeyer et al., 1983). The for-
mulations containing Kollidon and HPMC showed good line-
arity (R2: 0.9862 and 0.9821), with slope (n) values (0.5000 and
0.5023), respectively, indicating that diffusion is the dominant
mechanism of drug release with these formulations that may
be the cause of superimposing of the two dissolution curves.
Formulations of Carbopol and Marketed product also showed
high linearity (R2: 0.9946 and 0.9687), with a comparatively
high slope (n) value of (0.8141 and 0.8460), respectively. For-
mulation containing Eudragit showed linearity (R2: 0.8251),
with a comparatively low slope (n) value of (0.2226). These
(n) values, however, appear to indicate a coupling of diffusion
and erosion mechanisms, so, called anomalous diffusion. The
relative complexity of these formulations and their compo-
nents may indicate that the drug release is controlled by more
than one mechanism.Statistical results for the dissolution data of each polymer
(10–30%) were done at deﬁnite time points (1.0, 2.0, 4.0, 6.0
and 12.0 h) using a nonparametric analysis Kruskal–Wallis
Test (Nonparametric ANOVA, corrected for ties) followed
by Dunn’s Multiple Comparisons Test. Carbopol tablets
results (Table 4A) were of P value about 0.0252, considered
signiﬁcant and variation among column medians was signiﬁ-
cantly greater than expected by chance. Eudragit tablets results
(Table 4B) were of P value about 0.2843, considered not
26 W. Sakr et al.signiﬁcant and variation among column medians was not sig-
niﬁcantly greater than expected by chance. HPMC tablets re-
sults (Table 4C) were of P value about 0.0255, considered
signiﬁcant and variation among column medians was signiﬁ-
cantly greater than expected by chance. Kollidon SR tablets
results (Table 4D) were of P value about 0.4582, considered
not signiﬁcant and variation among column medians was not
signiﬁcantly greater than expected by chance.
4. Conclusion
Preliminary evaluation of Kollidon SR concerning matrix
system formation for controlling Albuterol Sulphate release
in comparison with other polymers showed the reliability of
Kollidon SR to be a good release rate modiﬁer for that highly
water soluble low dose drug which is in agreement with the
results obtained from the work of Draganoiu et al. (2001).
The pronounced binding properties of Carbopol were
remarkably reﬂected on tablet hardness producing hard tablets
more than other polymers used (Fig. 4). The longest time for
50% drug release was achieved by Carbopol 30% (w/w) while
the shortest time for 50% drug release was noticed with Eudra-
git L100-55 30% (w/w) (Fig. 5).
Kollidon SR and HPMC K15M matrix systems had similar
dissolution proﬁle to each other (f2 > 50) slowing the release
of Albuterol Sulphate from the matrix system. In addition,
Kollidon SR, as well as HPMC and Carbopol were found to
enhance the mechanical properties of tablets increasing hard-
ness and decreasing friability. Drug release from all previous
formulations is best described to be controlled by more than
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